Loading stock data…
ZLAB
$19.59+0.99 (+5.32%)
Market ClosedLast close May 11
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Zai Lab Limited in the Healthcare sector is trading at $19.59. The stock is currently near its 52-week low of $15.96, remaining 19.0% below its 200-day moving average. Technical signals show oversold RSI of 28 and bearish MACD signal, explaining why ZLAB maintains its current current market pressure. The Whystock Score of 25/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Oversold momentum (RSI 28) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$19.59
Potential Upside
5%
Whystock Fair Value$20.57
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus12 analysts
Mean target$34.39+75.6%
Range$21.60 – $52.00
Fundamentals
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products includ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.58B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.86
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-29.70%
Volume
Today's trading volume
978,929
Recent News
Asian Equities Traded in the US as American Depositary Receipts Open Week Lower in Monday Trading
Asian equities traded in the US as American depositary receipts opened the week tracking modestly lo
Zai Lab Limited (NASDAQ:ZLAB) Analysts Are Cutting Their Estimates: Here's What You Need To Know
It's been a mediocre week for Zai Lab Limited ( NASDAQ:ZLAB ) shareholders, with the stock dropping 12% to US$18.60 in...
Zai Lab Q1 Earnings Call Highlights
Zai Lab (NASDAQ:ZLAB) reported a year-over-year decline in first-quarter 2026 product revenue as pressure on ZEJULA weighed on results, while management emphasized progress across its global oncology and immunology pipeline and pointed to multiple upcoming regulatory and clinical milestones. On the
Asian Equities Traded in the US as American Depositary Receipts Edge Higher Friday
Asian equities traded in the US as American depositary receipts were edging higher Friday morning, r
Zai Lab Limited (ZLAB) Reports Q1 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Zai Lab Limited (ZLAB) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.